Can-Fite BioPharma


Roth Capital Reiterates Buy on Can-Fite BioPharma Following Distribution Agreement With Cipher

Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Can-Fite BioPharma Ltd (NYSEMKT:CANF) with a price target of $20, after the company signed …

Can-Fite Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research report issued this morning, H.C.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts